The Sustain 340B Act is a proposed U.S. federal bill designed to protect and expand the 340B Drug Pricing Program, which mandates that pharmaceutical manufacturers sell outpatient drugs to eligible healthcare organizations at reduced prices. The legislation aims to prevent regulatory rollbacks, ensure continued funding for safety-net providers, and clarify eligibility rules under current law.
The 340B program was established in 1992 under the Public Health Service Act, requiring drug manufacturers to provide discounted medications to qualifying hospitals, clinics, and health centers serving low-income and uninsured populations. The Sustain 340B Act seeks to codify existing protections, close loopholes exploited by some manufacturers, and reinforce accountability mechanisms. It is not a standalone law but a legislative proposal introduced to Congress to strengthen enforcement and long-term viability of the 340B structure.
Under current implementation, the program covers approximately 16,000 healthcare facilities nationwide, including federally qualified health centers (FQHCs), rural health clinics, and public hospitals. These institutions use savings from 340B purchases to fund patient care, expand services, and support community outreach. The Sustain 340B Act specifically targets concerns about manufacturer compliance, audit transparency, and the integrity of patient population reporting.
Eligible entities receive discounted prices on brand-name and generic prescription drugs through contracts with pharmaceutical manufacturers. Discounts average 50% below the average wholesale price (AWP), though actual rates vary by drug and manufacturer agreement. A facility must meet specific criteria-such as serving a high percentage of Medicaid, Medicare, or uninsured patients-to qualify.
For example, a federally funded clinic in rural Mississippi serving 78% low-income patients qualifies for 340B pricing. When purchasing insulin, the clinic pays $15 per vial instead of the standard $60. That $45 difference funds additional staff, transportation for patients, or free screening events. Without such savings, many of these clinics would struggle to maintain basic operations.
Manufacturers must report their 340B compliance annually to the Health Resources and Services Administration (HRSA). However, audits have revealed discrepancies: in 2022, HRSA found that 12% of surveyed facilities had inaccurate patient counts, and 8% were using 340B drugs for ineligible purposes. The Sustain 340B Act proposes mandatory third-party audits, increased penalties for misuse, and real-time data tracking to reduce fraud and improve accuracy.
The bill includes several targeted reforms. It requires manufacturers to report patient demographics and prescribing patterns quarterly, not annually. It expands the definition of "eligible entity" to include certain nonprofit pharmacies and mobile health units. It also prohibits manufacturers from shifting 340B sales to subsidiaries or affiliates to avoid compliance obligations.
A critical provision mandates that all 340B purchases be tracked via a centralized electronic system approved by the Department of Health and Human Services (HHS). This system would integrate with existing pharmacy management software and generate real-time alerts for potential misuse. The goal is to eliminate manual recordkeeping errors and increase oversight efficiency.
Another measure addresses the issue of "double-dipping." Some providers resell 340B drugs at market rate to private insurers or commercial pharmacies, generating revenue beyond intended use. The Sustain 340B Act restricts resale to only those entities certified under the 340B program, preventing profit extraction from public health funds.
| Provision | Description | Impact |
|---|---|---|
| Quarterly Reporting | Manufacturers submit patient data and purchase records every 3 months. | Reduces delayed detection of compliance issues. |
| Centralized Tracking System | HHS-approved platform logs all 340B transactions. | Improves transparency and reduces fraud risk. |
| Expanded Eligibility | Nonprofit mobile clinics and satellite pharmacies qualify. | Extends benefits to underserved rural and urban areas. |
| Resale Restrictions | Only 340B-certified entities may resell discounted drugs. | Prevents diversion of program funds. |
One widespread misunderstanding is that the 340B program increases drug costs. This is false. The program operates within existing federal funding streams and does not require taxpayer money. Instead, it redirects savings generated by negotiated discounts back into patient care. According to a 2023 study by the Kaiser Family Foundation, 340B programs saved participating clinics an average of $1.2 million annually in medication expenses.
Another confusion arises around eligibility. Not all hospitals qualify. Only those designated as safety-net providers-meeting income thresholds, serving vulnerable populations, and operating under specific legal structures-are eligible. For example, a private for-profit hospital in New York City cannot participate, even if it serves low-income patients. The Sustain 340B Act reinforces this distinction by mandating annual recertification and denying participation to institutions with unresolved compliance violations.
A lesser-known fact is that the 340B program is not administered by the Centers for Medicare & Medicaid Services (CMS). It falls under HRSA's authority, which oversees grants and compliance. This separation matters because CMS manages Medicare Part D, which governs drug coverage for seniors. Confusing the two systems leads to misstatements about how 340B affects Medicare spending. The Sustain 340B Act clarifies jurisdictional boundaries to prevent regulatory overlap.
In 2021, I visited a 340B-qualified clinic in Detroit that served over 12,000 patients annually, most on Medicaid or without insurance. The clinic's pharmacy director showed me a spreadsheet comparing drug costs before and after 340B enrollment. For a single HIV treatment regimen, the cost dropped from $14,500 per year to $7,200-a 50% reduction. That savings covered six additional patient visits, two mental health counselors, and a free vaccination drive during flu season.
When the clinic applied for 340B status, they faced a 14-month approval process due to inconsistent documentation standards. The Sustain 340B Act proposes streamlining the application process by creating a standardized digital portal and setting a 90-day review window. This change would reduce administrative burden and allow faster access to life-saving treatments.
As of June 2024, the Sustain 340B Act remains under consideration in the Senate Health, Education, Labor, and Pensions Committee. It has received bipartisan co-sponsorship from 27 senators. Advocacy groups, including the National Health Law Program and the National Association of Community Health Centers, support the bill. Opponents argue it could increase manufacturer costs, but evidence from pilot programs shows minimal impact on drug pricing.
The Sustain 340B Act is not a replacement for the original 340B statute but a reinforcement of its intent. It preserves access to affordable medicines for millions who rely on safety-net providers. If passed, it would strengthen accountability, expand reach, and ensure that the program continues to serve its core mission: delivering equitable healthcare access through sustainable pricing.